In their study, Halle and colleagues found that lymph node negative cervical cancer patients with high expression of ectodomain EGFR isoforms had a high probability of relapse after chemoradiotherapy, whereas the EGFR tyrosine kinase activity was of minor importance. Gene expression profiles of the tumors were used to further explore these findings. The study may shed light on possible mechanisms of treatment resistance in EGFR trials and point to the expression of ectodomain EGFR isoforms as a novel and well-needed biomarker of relapse for this group of patients.
The patients were treated at the Radium Hospital and clinical collaborators were Gunnar B. Kristensen and the radiotherapy team at the section for Gynecological Oncology. Collaborators in statistics and bioinformatics were Marit Holden at the Norwegian Computing Center and Trevor Clancy at Department of Tumorbiology.
Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node-Negative Cervical Cancer.
Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, Lyng H.
Clin Cancer Res. 2011 Aug 9.
Highlight article: EGFR Ectodomain Isoforms Predict Cervical Cancer Outcome
Heidi Lyngs project group
From major journals, first or last author from the Institute for Cancer Research
Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges
Adv Drug Deliv Rev, 114326 (in press)
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
Nucleic Acids Res (in press)
In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis
Mol Oncol (in press)